PTC Therapeutics CLO exercises options, sells shares
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sell transaction in company stock. On June 17, 2026, he exercised stock options to acquire a total of 10,522 shares of Common Stock at an exercise price of $46.54 per share.
On the same date he sold 10,462 shares in open-market transactions at weighted average prices around $78.50–$79.25 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025. Following these transactions, he directly holds 105,272 shares of PTC Therapeutics common stock.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
8 txns
Insider
Boulding Mark Elliott
Role
EXEC. VP AND CLO
Sold
10,462 shs ($823K)
Approx. gross sale proceeds
$823K
Approx. exercise cost
$490K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 8,510 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 2,012 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,510 | $46.54 | $396K |
| Sale | Common Stock | 6,600 | $78.50 | $518K |
| Sale | Common Stock | 1,850 | $79.24 | $147K |
| Exercise | Common Stock | 2,012 | $46.54 | $94K |
| Sale | Common Stock | 1,703 | $78.50 | $134K |
| Sale | Common Stock | 309 | $79.25 | $24K |
Holdings After Transaction:
Stock Option (Right to Buy) — 30,938 contracts (Direct);
Common Stock — 105,272 shares (Direct)
Footnotes (5)
- F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
- F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.00 to $78.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.00 to $79.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.00 to $79.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5. This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
Key Figures
Shares sold: 10,462 shares
Options exercised: 10,522 shares
Exercise price: $46.54 per share
+5 more
8 metrics
Shares sold
10,462 shares
Open-market sales on June 17, 2026
Options exercised
10,522 shares
Common Stock acquired via option exercise on June 17, 2026
Exercise price
$46.54 per share
Stock Option (Right to Buy) for Common Stock
Sale price example
$79.25 per share
One reported weighted average sale price on June 17, 2026
Sale price example
$78.50 per share
Another reported weighted average sale price on June 17, 2026
Post-transaction holdings
105,272 shares
Direct ownership of PTC Therapeutics common stock after trades
Option expiration
January 2, 2035
Expiration date of the exercised stock options
10b5-1 plan adoption date
September 10, 2025
Date written Rule 10b5-1 trading plan was adopted
Key Terms
Rule 10b5-1 plan, Stock Option (Right to Buy), weighted average price, derivative exercise/conversion, +1 more
5 terms
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with an exercise price of 46.5400 per share."
weighted average price financial
"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.00 to $78.99 per share."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" and transaction_code_description: "Exercise or conversion of derivative security"."
open-market sale financial
"transaction_action: "open-market sale" and transaction_code "S" for non-derivative Common Stock."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PTC Therapeutics (PTCT) report for Mark Elliott Boulding?
PTC Therapeutics reported that executive Mark Elliott Boulding exercised stock options and sold shares. He acquired 10,522 common shares through option exercises, then sold 10,462 shares in open-market trades while retaining 105,272 shares directly after the transactions.
What stock options did Mark Elliott Boulding exercise for PTC Therapeutics (PTCT)?
He exercised options covering 10,522 shares of PTC Therapeutics common stock at a $46.54 exercise price. The options were granted on January 3, 2025 and are scheduled to vest over four years, with an expiration date of January 2, 2035.
What is Mark Elliott Boulding’s role at PTC Therapeutics (PTCT) in this Form 4?
The Form 4 identifies Mark Elliott Boulding as an officer of PTC Therapeutics, serving as Executive Vice President and Chief Legal Officer. The reported transactions therefore reflect trading activity by a senior company executive.
AI-generated analysis. How Rhea-AI works. Not financial advice.
